OUTPATIENT SUBCUTANEOUS ALEMTUZUMAB IS FEASIBLE AND SAFE FOR APLASTIC ANEMIA AND ASSOCIATED WITH HIGH RESPONSE RATES
AR Fonsecaa,b, CC Justinoa, VC Mollaa,c, PE Yamakawaa, IB Rabeloa, A Hilld, L Arnoldd, R Kellyd, M Griffind, T Munird, E Vellosoe, T Dalessandroe, AM Risitanof,g, P Scheinbergh, A Kulasekararaji, C Arrais-Rodriguesa,c
a Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil
b Hospital Sírio Libanês, São Paulo, Brazil
c Hospital Nove de Julho, São Paulo, Brazil
d Department of Haematology, St James's University Hospital, Leeds, United Kingdom
e Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, Brazil
f Department of Clinical Medicine and Surgery, University of Naples, Naples, Italy
g Severe Aplastic Anemia Working Party, European Group for Blood and Marrow Transplantation (EBMT), Leiden, Netherlands
h Division of Hematology, Hospital A Beneficência Portuguesa, São Paulo, Brazil
i King's College Hospital NHS Foundation Trust, London, United Kingdom
Ver másLido
1439
Vezesque se leu este artigo
485
Total PDF
954
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 11 | 39 | 13 | 52 |
| 2025 10 | 55 | 22 | 77 |
| 2025 9 | 60 | 24 | 84 |
| 2025 8 | 39 | 20 | 59 |
| 2025 7 | 43 | 17 | 60 |
| 2025 6 | 39 | 22 | 61 |
| 2025 5 | 55 | 13 | 68 |
| 2025 4 | 41 | 12 | 53 |
| 2025 3 | 56 | 13 | 69 |
| 2025 2 | 52 | 14 | 66 |
| 2025 1 | 36 | 24 | 60 |
| 2024 12 | 28 | 12 | 40 |
| 2024 11 | 44 | 12 | 56 |
| 2024 10 | 42 | 26 | 68 |
| 2024 9 | 43 | 19 | 62 |
| 2024 8 | 52 | 17 | 69 |
| 2024 7 | 39 | 22 | 61 |
| 2024 6 | 34 | 19 | 53 |
| 2024 5 | 45 | 41 | 86 |
| 2024 4 | 33 | 17 | 50 |
| 2024 3 | 28 | 21 | 49 |
| 2024 2 | 18 | 22 | 40 |
| 2024 1 | 7 | 14 | 21 |
| 2023 12 | 11 | 18 | 29 |
| 2023 11 | 13 | 23 | 36 |
| 2023 10 | 2 | 8 | 10 |
Mostrar tudo
